Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...
The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback